Sitagliptin vs Teneligliptin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline

Sitagliptin · Januvia

Marketed by Merck & Co. and partners

Approved in Type 2 Diabetessmall molecule
Partial signal

NCT00087516 · Phase 3 · completed

The trial randomized 741 participants to double-blind sitagliptin or placebo groups, providing a substantial controlled comparison. The primary endpoint, change in A1C at week 24, was statistically favorable for both sitagliptin doses (p<0.001), but A1C is a surrogate endpoint, so the evidence is rated moderate rather than strong.

Next expected readout: September 2029 · NCT07108985 (registry estimate)

Reported efficacy

Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Sitagliptin 100 mg -0.85 Percent (95% CI -0.98 to -0.72) vs Placebo -0.15 Percent (95% CI -0.28 to -0.03) (met)

Result source: NCT00086502

Teneligliptin · Tenelia

Marketed by Tanabe Pharma Corporation and partners

Phase 3 in Type 2 Diabetessmall molecule
Partial signal

NCT00974090 · Phase 3 · completed

This randomized, double-blind, placebo-controlled Phase 3 trial added teneligliptin 20 mg or placebo to glimepiride in 194 Japanese adults with type 2 diabetes. The primary endpoint was the change in HbA1c at week 12. Teneligliptin lowered HbA1c by 1.0 percentage point more than placebo (p<0.001), so the primary endpoint was met. A 40-week open-label teneligliptin period followed. Source: the peer-reviewed trial report (Kadowaki and Kondo 2014) and CT.gov posted results.

Reported efficacy

HbA1c (Change from Visit 1(Baseline Visit) in HbA1c at Visit 5(week 16)): Change in HbA1c from baseline to week 16, teneligliptin (MP-513) vs placebo (both plus metformin): between-group difference -0.78 percentage points; fasting plasma glucose difference -1.24 mmol/L (22.42 mg/dL). (met)

Result source: NCT01805830

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointSitagliptinTeneligliptin
HbA1c, change-0.6% vs 0.2%−0.8 vs placebo100 mg · wk 24 · n 229NCT00087516
7 other results
  • -0.8% vs -0.1% 100 mg · wk 24 · n 163 · Phase 3 · primary NCT00086502
  • -0.8% vs 0.2% 200 mg · wk 24 · n 238 · Phase 3 · primary NCT00087516
  • -0.0% vs 0.2% wk 20 · n 95 · Phase 3 · primary NCT01485614
  • -1.1% vs -0.7% wk 20 · n 229 · Phase 3 · primary NCT02791490
  • -0.1% vs -1.0% wk 20 · n 78 · Phase 3 · primary NCT01485614
  • -0.2% vs -0.7% wk 54 · n 41 · Phase 3 · secondary NCT01485614
  • -0.5% vs -1.1% wk 26 · n 182 · Phase 4 · primary NCT01907854
-0.7% vs -0.0%−0.7 vs placebo20 mg · wk 24 · n 122NCT02924064
12 other results
  • -0.9% vs -0.1% 20 mg · wk 24 · n 125 · Phase 3 · primary NCT02916706
  • -0.6% vs 0.2% 20 mg · wk 12 · n 99 · Phase 3 · primary NCT00998881
  • -0.9% vs 0% wk 24 · n 77 · Phase 3 · primary NCT02354222
  • -0.7% vs 0.3% wk 12 · n 96 · Phase 3 · primary NCT00974090
  • -0.8% vs 0.1% 20 mg · wk 12 · n 79 · Phase 2 · primary NCT00628212
  • -0.8% vs 0.1% 10 mg · wk 12 · n 84 · Phase 2 · primary NCT00628212
  • -0.9% vs -0.3% 40 mg · wk 24 · n 88 · Phase 2 · primary NCT00971243
  • -0.9% vs 0.1% 40 mg · wk 12 · n 81 · Phase 2 · primary NCT00628212
  • -0.8% vs -0.3% 20 mg · wk 24 · n 91 · Phase 2 · primary NCT00971243
  • -0.7% vs -0.3% 10 mg · wk 24 · n 93 · Phase 2 · primary NCT00971243
  • -0.6% vs -0.3% 5 mg · wk 24 · n 87 · Phase 2 · primary NCT00971243
  • -0.9% vs -0.1% wk 16 · n 77 · Phase 4 · primary NCT02081599
Body weight, change (kg)-0.5 vs -1.4vs Oral Semaglutide100 mg · wk 26 · n 335NCT04017832
1 other result
  • -1.8 vs -3.3 wk 26 · n 200 · Phase 4 · secondary NCT01907854
—Not posted · NCT01798238
HbA1c below 7%49.5% vs 36.8%+12.7 vs placebowk 20 · n 95NCT01485614
4 other results
  • 28.8% vs 16.6% wk 20 · n 229 · Phase 3 · secondary NCT02791490
  • 15.6% vs 5.7% wk 20 · n 122 · Phase 3 · secondary NCT02791490
  • 28.4% vs 33.3% wk 54 · n 95 · Phase 3 · secondary NCT01485614
  • 49.5% vs 77.8% wk 20 · n 95 · Phase 3 · secondary NCT01485614
—Not posted · NCT01798238
Fasting plasma glucose, change-0.7 vs 0.3−0.9 vs placebo100 mg · wk 24 · n 234NCT00087516
7 other results
  • -0.9 vs 0.1 100 mg · wk 24 · n 163 · Phase 3 · secondary NCT00086502
  • -0.9 vs 0.3 200 mg · wk 24 · n 244 · Phase 3 · secondary NCT00087516
  • 0.4 vs 0.3 wk 20 · n 95 · Phase 3 · secondary NCT01485614
  • -1.6 vs -0.9 wk 20 · n 229 · Phase 3 · secondary NCT02791490
  • -0.5 vs -1.0 100 mg · wk 26 · n 329 · Phase 3 · secondary NCT04017832
  • 0.6 vs -1.1 wk 20 · n 81 · Phase 3 · secondary NCT01485614
  • -0.2 vs -1.7 wk 54 · n 44 · Phase 3 · secondary NCT01485614
-0.8 vs 0.2−0.9 vs placebo20 mg · wk 24 · n 122NCT02924064
13 other results
  • -1.2 vs -0.1 20 mg · wk 24 · n 125 · Phase 3 · secondary NCT02916706
  • -1.1 vs -0.0 20 mg · wk 12 · n 99 · Phase 3 · secondary NCT00998881
  • -1.1 vs -0.4 20 mg · wk 4 · n 33 · Phase 3 · secondary NCT01072331
  • -1.1 vs -0.4 10 mg · wk 4 · n 34 · Phase 3 · secondary NCT01072331
  • -0.3 vs 0.6 wk 24 · n 77 · Phase 3 · secondary NCT02354222
  • -0.8 vs 0.2 20 mg · wk 12 · n 79 · Phase 2 · secondary NCT00628212
  • -0.8 vs 0.2 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT00628212
  • -1.2 vs -0.2 40 mg · wk 24 · n 88 · Phase 2 · secondary NCT00971243
  • -0.9 vs 0.2 40 mg · wk 12 · n 81 · Phase 2 · secondary NCT00628212
  • -1.0 vs -0.2 20 mg · wk 24 · n 91 · Phase 2 · secondary NCT00971243
  • -0.8 vs -0.2 10 mg · wk 24 · n 93 · Phase 2 · secondary NCT00971243
  • -0.9 vs -0.2 5 mg · wk 24 · n 87 · Phase 2 · secondary NCT00971243
  • -0.3 vs 0.4 wk 16 · n 77 · Phase 4 · secondary NCT02081599
3-point MACE (% with event)—Not posted · NCT01529541—Not posted · NCT01798238

HbA1c, change

Sitagliptin
-0.6% vs 0.2%−0.8 vs placebo100 mg · wk 24 · n 229NCT00087516
7 other results
  • -0.8% vs -0.1% 100 mg · wk 24 · n 163 · Phase 3 · primary NCT00086502
  • -0.8% vs 0.2% 200 mg · wk 24 · n 238 · Phase 3 · primary NCT00087516
  • -0.0% vs 0.2% wk 20 · n 95 · Phase 3 · primary NCT01485614
  • -1.1% vs -0.7% wk 20 · n 229 · Phase 3 · primary NCT02791490
  • -0.1% vs -1.0% wk 20 · n 78 · Phase 3 · primary NCT01485614
  • -0.2% vs -0.7% wk 54 · n 41 · Phase 3 · secondary NCT01485614
  • -0.5% vs -1.1% wk 26 · n 182 · Phase 4 · primary NCT01907854
Teneligliptin
-0.7% vs -0.0%−0.7 vs placebo20 mg · wk 24 · n 122NCT02924064
12 other results
  • -0.9% vs -0.1% 20 mg · wk 24 · n 125 · Phase 3 · primary NCT02916706
  • -0.6% vs 0.2% 20 mg · wk 12 · n 99 · Phase 3 · primary NCT00998881
  • -0.9% vs 0% wk 24 · n 77 · Phase 3 · primary NCT02354222
  • -0.7% vs 0.3% wk 12 · n 96 · Phase 3 · primary NCT00974090
  • -0.8% vs 0.1% 20 mg · wk 12 · n 79 · Phase 2 · primary NCT00628212
  • -0.8% vs 0.1% 10 mg · wk 12 · n 84 · Phase 2 · primary NCT00628212
  • -0.9% vs -0.3% 40 mg · wk 24 · n 88 · Phase 2 · primary NCT00971243
  • -0.9% vs 0.1% 40 mg · wk 12 · n 81 · Phase 2 · primary NCT00628212
  • -0.8% vs -0.3% 20 mg · wk 24 · n 91 · Phase 2 · primary NCT00971243
  • -0.7% vs -0.3% 10 mg · wk 24 · n 93 · Phase 2 · primary NCT00971243
  • -0.6% vs -0.3% 5 mg · wk 24 · n 87 · Phase 2 · primary NCT00971243
  • -0.9% vs -0.1% wk 16 · n 77 · Phase 4 · primary NCT02081599

Body weight, change (kg)

Sitagliptin
-0.5 vs -1.4vs Oral Semaglutide100 mg · wk 26 · n 335NCT04017832
1 other result
  • -1.8 vs -3.3 wk 26 · n 200 · Phase 4 · secondary NCT01907854
Teneligliptin
—Not posted · NCT01798238

HbA1c below 7%

Sitagliptin
49.5% vs 36.8%+12.7 vs placebowk 20 · n 95NCT01485614
4 other results
  • 28.8% vs 16.6% wk 20 · n 229 · Phase 3 · secondary NCT02791490
  • 15.6% vs 5.7% wk 20 · n 122 · Phase 3 · secondary NCT02791490
  • 28.4% vs 33.3% wk 54 · n 95 · Phase 3 · secondary NCT01485614
  • 49.5% vs 77.8% wk 20 · n 95 · Phase 3 · secondary NCT01485614
Teneligliptin
—Not posted · NCT01798238

Fasting plasma glucose, change

Sitagliptin
-0.7 vs 0.3−0.9 vs placebo100 mg · wk 24 · n 234NCT00087516
7 other results
  • -0.9 vs 0.1 100 mg · wk 24 · n 163 · Phase 3 · secondary NCT00086502
  • -0.9 vs 0.3 200 mg · wk 24 · n 244 · Phase 3 · secondary NCT00087516
  • 0.4 vs 0.3 wk 20 · n 95 · Phase 3 · secondary NCT01485614
  • -1.6 vs -0.9 wk 20 · n 229 · Phase 3 · secondary NCT02791490
  • -0.5 vs -1.0 100 mg · wk 26 · n 329 · Phase 3 · secondary NCT04017832
  • 0.6 vs -1.1 wk 20 · n 81 · Phase 3 · secondary NCT01485614
  • -0.2 vs -1.7 wk 54 · n 44 · Phase 3 · secondary NCT01485614
Teneligliptin
-0.8 vs 0.2−0.9 vs placebo20 mg · wk 24 · n 122NCT02924064
13 other results
  • -1.2 vs -0.1 20 mg · wk 24 · n 125 · Phase 3 · secondary NCT02916706
  • -1.1 vs -0.0 20 mg · wk 12 · n 99 · Phase 3 · secondary NCT00998881
  • -1.1 vs -0.4 20 mg · wk 4 · n 33 · Phase 3 · secondary NCT01072331
  • -1.1 vs -0.4 10 mg · wk 4 · n 34 · Phase 3 · secondary NCT01072331
  • -0.3 vs 0.6 wk 24 · n 77 · Phase 3 · secondary NCT02354222
  • -0.8 vs 0.2 20 mg · wk 12 · n 79 · Phase 2 · secondary NCT00628212
  • -0.8 vs 0.2 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT00628212
  • -1.2 vs -0.2 40 mg · wk 24 · n 88 · Phase 2 · secondary NCT00971243
  • -0.9 vs 0.2 40 mg · wk 12 · n 81 · Phase 2 · secondary NCT00628212
  • -1.0 vs -0.2 20 mg · wk 24 · n 91 · Phase 2 · secondary NCT00971243
  • -0.8 vs -0.2 10 mg · wk 24 · n 93 · Phase 2 · secondary NCT00971243
  • -0.9 vs -0.2 5 mg · wk 24 · n 87 · Phase 2 · secondary NCT00971243
  • -0.3 vs 0.4 wk 16 · n 77 · Phase 4 · secondary NCT02081599

3-point MACE (% with event)

Sitagliptin
—Not posted · NCT01529541
Teneligliptin
—Not posted · NCT01798238
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
5 other shared endpoints and safety

Coverage. Sitagliptin: 9 of 9 rows · Teneligliptin: 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricSitagliptin
Rows use multiple source trials
Teneligliptin
Rows use multiple source trials
Fasting Plasma Glucose
absolute change · mmol/L
No placebo or comparator arm
-0.23 mmol/L @ 104wk*100 mga,b,c
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -4.1 mg/dL as posted
show 3 more doses
-0.1 mmol/L @ 104wk*100 mg/100 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -1.8 mg/dL as posted
-0.23 mmol/L @ 104wk*200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -4.1 mg/dL as posted
-0.32 mmol/L @ 104wk*200 mg/200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -5.7 mg/dL as posted
-0.69 mmol/L @ 52wk*a,b,c
NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -12.4 mg/dL as posted
show 1 more dose
-0.94 mmol/L @ 52wk*
NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -17 mg/dL as posted
Glucose Change mg/dL
absolute change · mmol/L
-1.06 vs -1.93 Glibenclamide mmol/L @ 1.857wk*50 mgd,e,f,g
NCT02318693 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -19.1 mg/dL as posted
-1.72 vs -0.3 placebo mmol/L @ 4wk*20 mga,d,e,f,g
NCT01072331 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -30.921 mg/dL as posted
show 1 more dose
-1.93 vs -0.3 placebo mmol/L @ 4wk*10 mg
NCT01072331 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -34.722 mg/dL as posted
HbA1c
absolute change · percentage points
No placebo or comparator arm
-1.27% (n=183) @ 24wka,d,e,f
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
show 2 more doses
-1.51% (n=189) @ 24wk
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
-1.15% (n=187) @ 24wk
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
-0.94% @ 24wkteneligliptin 20mgd,e,f
NCT01798238 · Phase 3 · sponsor-reported, not registry data
PPG 2h Change mg/dL
absolute change · mmol/L
-6.01 vs -2.47 Sitagliptin mmol/L @ 8wk*d,e,f,h
NCT00729326 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -108.35 mg/dL as posted
-1.96 vs 0.13 placebo mmol/L @ 24wk*d,e,f,h
NCT02354222 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -35.3 mg/dL as posted
Weight
percent change · % of baseline
-1% (n=335) vs -2% (n=322) Oral Semaglutide @ 26wk100 mge,f,i
NCT04017832 · Phase 3 · registry result, not featured evidence
0.09% (n=77) vs -1.34% (n=76) placebo @ 24wke,f,i
NCT02354222 · Phase 3 · registry result, not featured evidence · combination
Dropout rate
74.6%100 mgj
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 37 more results
67.6%100 mg/100 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
69.1%200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
67.6%200 mg/200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
14.9%100 mg
NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3
9%
NCT02556918 · Phase 4 · registry result, not featured evidence
—100 mg
NCT03267576 · Phase 4 · registry result, not featured evidence
0%
NCT02920918 · Phase 4 · registry result, not featured evidence
—Sitagliptin (Diabetics and Control
NCT02639637 · Phase 4 · registry result, not featured evidence
—Sitagliptin and Valsartan (Control
NCT02639637 · Phase 4 · registry result, not featured evidence · combination
—
NCT02256189 · Phase 4 · registry result, not featured evidence
—
NCT01859793 · Phase 4 · registry result, not featured evidence
0%
NCT02312063 · Phase 4 · registry result, not featured evidence
—Metformin and Sitagliptin
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
0.7%Sitagliptin + Glargine (Hospital)
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
0%50 mg
NCT02318693 · Phase 4 · registry result, not featured evidence
6.4%
NCT01907854 · Phase 4 · registry result, not featured evidence
—
NCT01686932 · Phase 4 · registry result, not featured evidence
10.8%BID + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
6.7%BID + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
6.2%OD + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
—Metformin Plus Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence · combination
—Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence
12.9%Sitagliptin + SSI Prn
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
—Sitagliptin and Glargine + SSI
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
3%
NCT01131182 · Phase 4 · registry result, not featured evidence
20.5%Exenatide + Placebo
NCT00870194 · Phase 4 · registry result, not featured evidence
10.9%Exenatide + Sitagliptin
NCT00870194 · Phase 4 · registry result, not featured evidence · combination
5.6%
NCT00686634 · Phase 4 · registry result, not featured evidence
—
NCT00729326 · Phase 4 · registry result, not featured evidence
2.5%100 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
1%
NCT01485614 · Phase 3 · registry result, not featured evidence
4.8%Sitagliptin/Metformin
NCT01760447 · Phase 3 · registry result, not featured evidence
10.6%Sitagliptin/Metformin XR
NCT01760447 · Phase 3 · registry result, not featured evidence
2.6%
NCT03115112 · Phase 3 · registry result, not featured evidence
1.3%
NCT02791490 · Phase 3 · registry result, not featured evidence
1%Teneli / Teneli + SUk
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 28 more results
—Teneli/Teneli + SU (Data Through W
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
—Teneli/Teneli + SU (Data Through W
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
10.6%Teneligliptin
NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
15.7%Teneligliptin + Sulfonylurea
NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.6%Teneli (Teneligliptin) /Teneli + I
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
—Teneli (Teneligliptin) /Teneli + I
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
—Teneli (Teneligliptin)/Teneli + In
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
19.5%20 mg
NCT02924064 · Phase 3 · registry result, not featured evidence · combination
11.8%20 mg
NCT02916706 · Phase 3 · registry result, not featured evidence
7.2%
NCT02220907 · Phase 3 · registry result, not featured evidence · combination
5.2%
NCT02354222 · Phase 3 · registry result, not featured evidence · combination
7.1%Teneligliptin
NCT01301833 · Phase 3 · registry result, not featured evidence
9.3%Teneligliptin and Alpha-glucosidas
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
7.4%Teneligliptin and Biguanide
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
10%Teneligliptin and Glinide
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
0%20 mg
NCT01072331 · Phase 3 · registry result, not featured evidence
0%10 mg
NCT01072331 · Phase 3 · registry result, not featured evidence
2%20 mg
NCT00998881 · Phase 3 · registry result, not featured evidence
—40 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
15.9%40 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
—20 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
20.9%20 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
—10 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
11.8%10 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
21.8%5 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
3.8%20 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
1.2%10 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
6.2%40 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
2.3%100 mgj
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 37 more results
4.2%100 mg/100 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.9%200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
4%200 mg/200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
6.3%100 mg
NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3
—
NCT02556918 · Phase 4 · registry result, not featured evidence
—100 mg
NCT03267576 · Phase 4 · registry result, not featured evidence
—
NCT02920918 · Phase 4 · registry result, not featured evidence
—Sitagliptin (Diabetics and Control
NCT02639637 · Phase 4 · registry result, not featured evidence
—Sitagliptin and Valsartan (Control
NCT02639637 · Phase 4 · registry result, not featured evidence · combination
—
NCT02256189 · Phase 4 · registry result, not featured evidence
—
NCT01859793 · Phase 4 · registry result, not featured evidence
—
NCT02312063 · Phase 4 · registry result, not featured evidence
—Metformin and Sitagliptin
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Sitagliptin + Glargine (Hospital)
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—50 mg
NCT02318693 · Phase 4 · registry result, not featured evidence
—
NCT01907854 · Phase 4 · registry result, not featured evidence
—
NCT01686932 · Phase 4 · registry result, not featured evidence
1.5%BID + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
1.5%BID + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
0%OD + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
—Metformin Plus Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence · combination
—Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence
—Sitagliptin + SSI Prn
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
—Sitagliptin and Glargine + SSI
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
—
NCT01131182 · Phase 4 · registry result, not featured evidence
7.9%Exenatide + Placebo
NCT00870194 · Phase 4 · registry result, not featured evidence
3.9%Exenatide + Sitagliptin
NCT00870194 · Phase 4 · registry result, not featured evidence · combination
—
NCT00686634 · Phase 4 · registry result, not featured evidence
—
NCT00729326 · Phase 4 · registry result, not featured evidence
—100 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
—
NCT01485614 · Phase 3 · registry result, not featured evidence
—Sitagliptin/Metformin
NCT01760447 · Phase 3 · registry result, not featured evidence
—Sitagliptin/Metformin XR
NCT01760447 · Phase 3 · registry result, not featured evidence
0.5%
NCT03115112 · Phase 3 · registry result, not featured evidence
—
NCT02791490 · Phase 3 · registry result, not featured evidence
1%Teneli / Teneli + SUk
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 28 more results
—Teneli/Teneli + SU (Data Through W
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
—Teneli/Teneli + SU (Data Through W
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.6%Teneligliptin
NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
9%Teneligliptin + Sulfonylurea
NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%Teneli (Teneligliptin) /Teneli + I
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
—Teneli (Teneligliptin) /Teneli + I
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
—Teneli (Teneligliptin)/Teneli + In
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
1.6%20 mg
NCT02924064 · Phase 3 · registry result, not featured evidence · combination
0%20 mg
NCT02916706 · Phase 3 · registry result, not featured evidence
4.6%
NCT02220907 · Phase 3 · registry result, not featured evidence · combination
0%
NCT02354222 · Phase 3 · registry result, not featured evidence · combination
3.3%Teneligliptin
NCT01301833 · Phase 3 · registry result, not featured evidence
6.7%Teneligliptin and Alpha-glucosidas
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
5.3%Teneligliptin and Biguanide
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
6.3%Teneligliptin and Glinide
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
—20 mg
NCT01072331 · Phase 3 · registry result, not featured evidence
—10 mg
NCT01072331 · Phase 3 · registry result, not featured evidence
2%20 mg
NCT00998881 · Phase 3 · registry result, not featured evidence
—40 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
2.3%40 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
—20 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
2.2%20 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
—10 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
3.2%10 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
2.3%5 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
1.3%20 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
0%10 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
2.5%40 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
Serious AEs
7.7%100 mgj
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 37 more results
10.1%100 mg/100 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
10.6%200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
10%200 mg/200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.9%100 mg
NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3
80%
NCT02556918 · Phase 4 · registry result, not featured evidence
0%100 mg
NCT03267576 · Phase 4 · registry result, not featured evidence
5.3%
NCT02920918 · Phase 4 · registry result, not featured evidence
0%Sitagliptin (Diabetics and Control
NCT02639637 · Phase 4 · registry result, not featured evidence
0%Sitagliptin and Valsartan (Control
NCT02639637 · Phase 4 · registry result, not featured evidence · combination
0%
NCT02256189 · Phase 4 · registry result, not featured evidence
0%
NCT01859793 · Phase 4 · registry result, not featured evidence
0%
NCT02312063 · Phase 4 · registry result, not featured evidence
—Metformin and Sitagliptin
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
7.2%Sitagliptin + Glargine (Hospital)
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
0%50 mg
NCT02318693 · Phase 4 · registry result, not featured evidence
3.4%
NCT01907854 · Phase 4 · registry result, not featured evidence
2%
NCT01686932 · Phase 4 · registry result, not featured evidence
3.6%BID + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
2.6%BID + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
2.1%OD + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
0%Metformin Plus Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence · combination
0%Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence
3.7%Sitagliptin + SSI Prn
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
0%Sitagliptin and Glargine + SSI
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
0%
NCT01131182 · Phase 4 · registry result, not featured evidence
3.1%Exenatide + Placebo
NCT00870194 · Phase 4 · registry result, not featured evidence
4.7%Exenatide + Sitagliptin
NCT00870194 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00686634 · Phase 4 · registry result, not featured evidence
2.7%
NCT00729326 · Phase 4 · registry result, not featured evidence
4.2%100 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
10.5%
NCT01485614 · Phase 3 · registry result, not featured evidence
6.5%Sitagliptin/Metformin
NCT01760447 · Phase 3 · registry result, not featured evidence
6.7%Sitagliptin/Metformin XR
NCT01760447 · Phase 3 · registry result, not featured evidence
2.1%
NCT03115112 · Phase 3 · registry result, not featured evidence
1.3%
NCT02791490 · Phase 3 · registry result, not featured evidence
—Teneli / Teneli + SUk
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 28 more results
0%Teneli/Teneli + SU (Data Through W
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
7.3%Teneli/Teneli + SU (Data Through W
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
4%Teneligliptin
NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
7.9%Teneligliptin + Sulfonylurea
NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3
—Teneli (Teneligliptin) /Teneli + I
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
6.5%Teneli (Teneligliptin) /Teneli + I
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
1.3%Teneli (Teneligliptin)/Teneli + In
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
3.2%20 mg
NCT02924064 · Phase 3 · registry result, not featured evidence · combination
4.7%20 mg
NCT02916706 · Phase 3 · registry result, not featured evidence
7.2%
NCT02220907 · Phase 3 · registry result, not featured evidence · combination
1.3%
NCT02354222 · Phase 3 · registry result, not featured evidence · combination
6.6%Teneligliptin
NCT01301833 · Phase 3 · registry result, not featured evidence
8%Teneligliptin and Alpha-glucosidas
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
6.3%Teneligliptin and Biguanide
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
3.8%Teneligliptin and Glinide
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
0%20 mg
NCT01072331 · Phase 3 · registry result, not featured evidence
0%10 mg
NCT01072331 · Phase 3 · registry result, not featured evidence
0%20 mg
NCT00998881 · Phase 3 · registry result, not featured evidence
5.7%40 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
—40 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
3.3%20 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
—20 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
4.3%10 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
—10 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
4.6%5 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
0%20 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
0%10 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
0%40 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
100 mgj
upper respiratory tract infection 13.1%
dizziness 11.5%
nasopharyngitis 9.2%
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 30 more results
100 mg/100 mg
upper respiratory tract infection 15.1%
dizziness 10.5%
nasopharyngitis 8.8%
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
200 mg
upper respiratory tract infection 11.4%
arthralgia 9.8%
blood glucose increased 8.9%
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
200 mg/200 mg
upper respiratory tract infection 16.4%
dizziness 12.4%
influenza 8.8%
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
100 mg
any infections and infestations 6.3% (placebo 3.4%)
upper respiratory tract infection 6.3% (placebo 3.4%)
any nervous system disorders 5.1% (placebo 3.9%)
NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3
infection 2% (placebo 2%)
headache 1% (placebo 1%)
loss of appetite 1% (placebo 0%)
NCT02556918 · Phase 4 · registry result, not featured evidence
100 mg
headache 1.6%
hypertension 1.6%
diarrhoea 0%
NCT03267576 · Phase 4 · registry result, not featured evidence
acute kidney injury 15.8%
arrhythmic events 5.3%
genital infection 5.3%
NCT02920918 · Phase 4 · registry result, not featured evidence
light-headedness 7.7% (placebo 7.7%)
paresthesias 7.7% (placebo 0%)
nausea 0% (placebo 7.7%)
NCT02639637 · Phase 4 · registry result, not featured evidence
light-headedness 0% (placebo 7.7%)
nausea 0% (placebo 7.7%)
paresthesias 0% (placebo 0%)
NCT02639637 · Phase 4 · registry result, not featured evidence · combination
rash 0% (placebo 2.8%)
NCT01859793 · Phase 4 · registry result, not featured evidence
hypoglycemia 0%
NCT02312063 · Phase 4 · registry result, not featured evidence
urinary tract infection 1.4%
wound infection 0%
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
50 mg
erythema 38.5%
hypoglycaemia 7.7%
periodontitis 7.7%
NCT02318693 · Phase 4 · registry result, not featured evidence
diarrhoea 9.3%
nausea 7.8%
upper respiratory tract infection 6.4%
NCT01907854 · Phase 4 · registry result, not featured evidence
hypoglycaemia 14%
blood glucose decreased 6%
NCT01686932 · Phase 4 · registry result, not featured evidence
influenza 5.7%
nasopharyngitis 4.7%
diarrhoea 4.2%
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
headache 5.7%
nasopharyngitis 5.7%
influenza 2.6%
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
diarrhoea 5.3%
influenza 5.3%
headache 4.2%
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
hyperglycemia 11.1%
pressure ulcer/skin ulcer 11.1%
hypoglycemia 3.7%
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
hypoglycemia 6.9%
pneumonia 6.9%
urinary tract infection 6.9%
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
headache 4.9%
dizziness 3.9%
hyperhidrosis 3.7%
NCT01131182 · Phase 4 · registry result, not featured evidence
nausea 15.7%
vomiting 10.2%
nasopharyngitis 8.7%
NCT00870194 · Phase 4 · registry result, not featured evidence
nausea 10.2%
nasopharyngitis 7.8%
headache 7%
NCT00870194 · Phase 4 · registry result, not featured evidence · combination
nausea 37%
vomiting 20.5%
headache 12.3%
NCT00729326 · Phase 4 · registry result, not featured evidence
100 mg
upper respiratory tract infection 7.8%
diarrhoea 4.5%
nausea 3.9%
NCT04017832 · Phase 3 · registry result, not featured evidence
hypoglycaemia 16.8%
nasopharyngitis 15.8%
upper respiratory tract infection 12.6%
NCT01485614 · Phase 3 · registry result, not featured evidence
hypoglycaemia 16.1%
upper respiratory tract infection 14.5%
diarrhoea 11.3%
NCT01760447 · Phase 3 · registry result, not featured evidence
hypoglycaemia 20%
upper respiratory tract infection 11.1%
abdominal pain 8.9%
NCT01760447 · Phase 3 · registry result, not featured evidence
nasopharyngitis 13%
hypoglycemia 5.2%
influenza 5.2%
NCT03115112 · Phase 3 · registry result, not featured evidence
diarrhoea 7.9% (placebo 4.8%)
NCT02791490 · Phase 3 · registry result, not featured evidence
k
nasopharyngitis 19.8% (placebo 27.4%)
upper respiratory tract inflammation 5.2% (placebo 7.4%)
alanine aminotransferase increased 4.2% (placebo 3.2%)
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 23 more results
nasopharyngitis 33.3% (placebo 27.4%)
protein urine present 16.7% (placebo 13.7%)
glucose urine present 11.5% (placebo 17.9%)
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
nasopharyngitis 37.1%
blood creatine phosphokinase increased 9.3%
protein urine present 9.3%
NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
nasopharyngitis 32.6%
glucose urine present 18%
protein urine present 14.6%
NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3
nasopharyngitis 28.6% (placebo 18.3%)
hypoglycaemia 27.3% (placebo 7%)
constipation 10.4% (placebo 2.8%)
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
hypoglycaemia 11.7% (placebo 7%)
nasopharyngitis 7.8% (placebo 18.3%)
constipation 3.9% (placebo 2.8%)
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
20 mg
upper respiratory tract infection 11.3% (placebo 17.9%)
hyperuricaemia 8.9% (placebo 10.6%)
hyperlipidaemia 6.5% (placebo 5.7%)
NCT02924064 · Phase 3 · registry result, not featured evidence · combination
20 mg
upper respiratory tract infection 23.6% (placebo 15.7%)
hyperuricaemia 8.7% (placebo 4.7%)
proteinuria 7.1% (placebo 3.9%)
NCT02916706 · Phase 3 · registry result, not featured evidence
nasopharyngitis 30.7%
pollakiuria 6.5%
constipation 5.2%
NCT02220907 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 15.6% (placebo 10.4%)
upper respiratory tract infection 5.2% (placebo 0%)
NCT02354222 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 29.2%
upper respiratory tract inflammation 9.4%
blood urine present 7.1%
NCT01301833 · Phase 3 · registry result, not featured evidence
nasopharyngitis 28%
upper respiratory tract inflammation 10.7%
eczema 9.3%
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 29.5%
upper respiratory tract inflammation 10.5%
blood urine present 9.5%
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 23.8%
upper respiratory tract inflammation 13.8%
bronchitis 8.8%
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
20 mg
nasopharyngitis 6.1% (placebo 0%)
blood triglycerides increased 3% (placebo 3.1%)
diarrhoea 3% (placebo 0%)
NCT01072331 · Phase 3 · registry result, not featured evidence
10 mg
upper respiratory tract inflammation 8.8% (placebo 0%)
nasopharyngitis 5.9% (placebo 0%)
alanine aminotransferase increased 2.9% (placebo 0%)
NCT01072331 · Phase 3 · registry result, not featured evidence
20 mg
nasopharyngitis 12.1% (placebo 6.7%)
glucose urine present 4% (placebo 6.7%)
upper respiratory tract inflammation 4% (placebo 3.8%)
NCT00998881 · Phase 3 · registry result, not featured evidence
40 mg
nasopharyngitis 8% (placebo 6.8%)
cystitis 5.7% (placebo 1.1%)
gastroenteritis 3.4% (placebo 2.3%)
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
20 mg
diarrhoea 5.5% (placebo 3.4%)
headache 5.5% (placebo 1.1%)
hypertension 3.3% (placebo 2.3%)
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
10 mg
cystitis 4.3% (placebo 1.1%)
nasopharyngitis 4.3% (placebo 6.8%)
bronchitis 3.2% (placebo 1.1%)
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
5 mg
nasopharyngitis 6.9% (placebo 6.8%)
hypertension 5.7% (placebo 2.3%)
bronchitis 3.4% (placebo 1.1%)
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
20 mg
nasopharyngitis 11.4% (placebo 13.8%)
glucose urine present 5.1% (placebo 7.5%)
urine ketone body present 5.1% (placebo 1.3%)
NCT00628212 · Phase 2 · registry result, not featured evidence
10 mg
nasopharyngitis 19% (placebo 13.8%)
blood creatine phosphokinase increased 4.8% (placebo 1.3%)
blood urine present 4.8% (placebo 1.3%)
NCT00628212 · Phase 2 · registry result, not featured evidence
40 mg
nasopharyngitis 17.3% (placebo 13.8%)
arthropod sting 3.7% (placebo 0%)
glucose urine present 3.7% (placebo 7.5%)
NCT00628212 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation context differs: baseline_threshold differs (none recorded versus hba1c>=6.9); comorbidity_diabetes differs (required versus none recorded).
  3. cAssessment timepoints differ: 104 weeks versus 52 weeks.
  4. dTrial phases differ: Phase 4 versus Phase 3.
  5. ePopulation comparability has not been reviewed for both studies.
  6. fTreatment context has not been resolved for both arms.
  7. gAssessment timepoints differ: 1.857 weeks versus 4 weeks.
  8. hAssessment timepoints differ: 8 weeks versus 24 weeks.
  9. iAssessment timepoints differ: 26 weeks versus 24 weeks.
  10. jPopulation comparability has not been reviewed for 33 of these studies.
  11. kPopulation comparability has not been reviewed for 24 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Sitagliptin

PMG 2-hr Change mg/dL -48.9 vs -2.2 placebo mg/dL @ 24wk100 mg
absolute change · mg/dL
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
-56.3 vs -2.2 placebo mg/dL @ 24wk200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.9 vs -6.8 Metformin mg/dL @ 20wk
NCT01485614 · Phase 3 · registry result, not featured evidence
-1.7 vs -39.7 Metformin mg/dL @ 54wk
NCT01485614 · Phase 3 · registry result, not featured evidence
PMG 2-hr Change mg/dL -30.5 mg/dL @ 104wk100 mg/100 mg
absolute change · mg/dL
No placebo or comparator arm
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
-38.3 mg/dL @ 104wk100 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
-41.5 mg/dL @ 104wk200 mg/200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
-35.5 mg/dL @ 104wk200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
Hyperglycemia 83.5% (n=91) vs 74.7% (n=91) placebo @ 0.29wk
event count · % of participants
NCT02556918 · Phase 4 · registry result, not featured evidence · converted to % from 76 Participants as posted
show 1 more result
5.5% (n=91) vs 3.3% (n=91) placebo @ 0.29wk*
NCT02556918 · Phase 4 · registry result, not featured evidence · converted to % from 5 Participants as posted
Persistent Hyperglycemia 63.7% (n=91) vs 64.8% (n=91) placebo @ 1.43wk
event count · % of participants
NCT02556918 · Phase 4 · registry result, not featured evidence · converted to % from 58 Participants as posted
Glucose 148.7 vs 149.8 placebo mmol/L @ 0.29wk
absolute value · mmol/L
NCT02556918 · Phase 4 · registry result, not featured evidence
show 2 more results
154.2 vs 156.5 placebo mmol/L @ 1.43wk
NCT02556918 · Phase 4 · registry result, not featured evidence
9.5 vs 9.4 Basal Bolus mmol/L
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
Hyperglycemia Ge 300 mg/dL 22% (n=91) vs 13.2% (n=91) placebo @ 1.43wk
event count · % of participants
NCT02556918 · Phase 4 · registry result, not featured evidence · converted to % from 20 Participants as posted
Severe Hypoglycemia Event Incidence 0% vs 0% placebo @ 0.29wk
event rate · count
NCT02556918 · Phase 4 · registry result, not featured evidence
show 1 more result
0% vs 0% placebo @ 1.43wk
NCT02556918 · Phase 4 · registry result, not featured evidence
Peak VO2 Change mL/Min -0.53 vs 0.67 Canagliflozin kg @ 12wk
absolute change · kg
NCT02920918 · Phase 4 · registry result, not featured evidence
Ventilatory Efficiency Change Slope -0.3 vs -0.3 Canagliflozin Unitless @ 12wk
absolute change · Unitless
NCT02920918 · Phase 4 · registry result, not featured evidence
FMD 5.8% (n=30) vs 6% (n=30) placebo @ 8wk
absolute change · percentage points
Following 8 weeks of therapy
NCT01859793 · Phase 4 · registry result, not featured evidence
Time in Tight Range 30.7% (n=138) vs 29.7% (n=139) Basal Bolus
absolute value · percentage points
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
Time in Range 57% (n=138) vs 59.6% (n=139) Basal Bolus
absolute value · percentage points
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
show 2 more results
36% (n=27) vs 43% (n=26) Glargine and Lispro @ 0.14wk
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
43% (n=29) vs 43% (n=26) Glargine and Lispro @ 0.14wk
NCT01378117 · Phase 4 · registry result, not featured evidence · combination

+ 68 further endpoints in the CSV export.

Teneligliptin

FPG -0.96 vs 0.54 placebo mmol/L @ 12wk
absolute change · mmol/L
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -17.3 mg/dL as posted
AUC0-2h PPG -73.124 vs 0.224 placebo mg @ 12wk20 mg
absolute change · mg
NCT00998881 · Phase 3 · registry result, not featured evidence
show 5 more results
-73.211 vs 5.897 placebo mg @ 12wk20 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
-65.445 vs 5.897 placebo mg @ 12wk10 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
-75.326 vs 5.897 placebo mg @ 12wk40 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
-65.544 vs 15.514 placebo mg @ 12wk
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
-54.035 vs 9.827 placebo mg @ 16wk
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
PPG 2 h -2.39 vs 0.33 placebo mmol/L @ 12wk
absolute change · mmol/L
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -43.1 mg/dL as posted
Weight -3.92% (n=152) @ 52wk
percent change · % of baseline
No placebo or comparator arm
NCT02220907 · Phase 3 · registry result, not featured evidence · combination
AUC0-2h PPG -2.79 vs 0.32 placebo mmol/L @ 24wk
absolute change · mmol/L
NCT02354222 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -50.2 mg/dL as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Sitagliptin's landscape · Teneligliptin's landscape